化学
前列腺癌
四聚体
荧光
前列腺
生物物理学
骨显像
癌症研究
生物化学
癌症
核医学
内科学
酶
医学
物理
生物
量子力学
作者
Longfei Zhang,Xiaojing Shi,Yuying Li,Xiaojiang Duan,Xing Yang,Zhenhua Hu,Mengchao Cui
标识
DOI:10.1021/acs.jmedchem.3c01895
摘要
(S)-3-(Carboxyformamido)-2-(3-(carboxymethyl)ureido)propanoic acid (EuK) is a known binder toward the prostate-specific membrane agent (PSMA) with strong affinity, making it a popular choice for prostate cancer medicine development. However, during the probe modification, a new EuK-based PSMA tetramer, Bone-1064, was discovered to have an unexpected and intense uptake in bone, which has not yet been reported in any previous studies yet. After administration, Bone-1064 allowed for high contrast visualization of the bone from surrounding tissues with a signal-to-background ratio of 10.22 at 24 h postinjection. In contrast, the tumor had a blurry contour, and the maximum tumor-to-normal-tissue ratio was only 2.22. Further imaging studies revealed that Bone-1064 binds specifically to hydroxyapatite in bone tissues, instead of PSMA. Overall, Bone-1064 is an excellent bone probe with a unique structure that can be used for NIR-II fluorescence imaging in animal models. Meanwhile, this modification study might also inspire further PSMA probe designations.
科研通智能强力驱动
Strongly Powered by AbleSci AI